SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles sharp selloff and reversal of gains after an upbeat investor-day outlook dominate discussion, with traders questioning whether its AI backlog can justify heavy spending and debt before cash flow improves. Some see the funding and cash-flow plan as reassurance, while others blame broader tech weakness and reaction to Google and Amazon results for renewed selling.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 report is the main focus, with traders debating whether strong results and higher guidance can clear an elevated bar as AI stocks face pressure. Bulls expect continued growth in its AI business, while bears argue that even a beat may not justify the valuation and could prompt further selling.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to a fresh 52-week high has traders focused on the upcoming Q3 results and BRIUMVIs growth, with the subcutaneous BRIUMVI readout also viewed as a potential catalyst. Heavy call activity and high short interest are fueling squeeze and buyout speculation, though the community disagrees on whether the rally reflects positioning around company fundamentals or an unconfirmed deal rumor.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,251,440,068.9505 in circulation. The last known price of Stellar is 0.16728777 USD and is down -1.15 over the last 24 hours. It is currently trading on 848 active market(s) with $82,083,533.38 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLM is drawing attention for persistent selling and weak price action, with traders saying it struggles to hold key levels and underperforms despite institutional-adoption headlines. The debate centers on whether DTCC and real-world-asset tokenization developments will eventually support the token, while skeptics argue that low fees and token economics may limit any price impact; some also allege ongoing SDF selling.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforces planned acquisition of Braze has drawn attention, with traders weighing the strategic boost to its AI-powered marketing and customer-engagement offerings against concerns about the deals price and integration risks. The discussion also reflects broader debate over whether AI will strengthen or disrupt established software platforms.

Pepe (PEPE) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Pepe has a current supply of 413,772,350,098,130.40630647. The last known price of Pepe is 0.00000489 USD and is down -3.02 over the last 24 hours. It is currently trading on 729 active market(s) with $389,285,493.23 traded over the last 24 hours. More information can be found at https://www.pepe.vip/.

Pepe

PEPE is drawing attention for volatile, largely range-bound trading, with traders watching repeated tests of resistance and debating whether rebounds signal a breakout or another short-lived pump. Dip-buying and accumulation calls contrast with concerns about continued declines, pump-and-dump behavior, and moves tracking broader crypto-market weakness.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens Phase 3 lung-cancer data for IMDELLTRA with AstraZenecas IMFINZI, showing a lower risk of death in extensive-stage small-cell lung cancer, is driving attention. Traders view the result as a promising oncology growth catalyst, alongside discussion of Repathas growth and Amgens upcoming earnings.

Hyperliquid (HYPE) is a cryptocurrency and operates on the Hyperliquid platform. Hyperliquid has a current supply of 950,394,442.10256707 with 253,500,314.85654783 in circulation. The last known price of Hyperliquid is 87.94735104 USD and is down -0.18 over the last 24 hours. It is currently trading on 350 active market(s) with $1,050,863,479.79 traded over the last 24 hours. More information can be found at https://hyperliquid.xyz/.

Hype

Hyperliquids HYPE is drawing attention for its strong rally toward record highs, with traders focused on revenue-funded token buybacks and burns and growing institutional access to its trading platform. Bullish calls about the protocols growth and token demand are tempered by concerns about volatility, pullbacks, and profit-taking.

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Liquidia Corp

Liquidias settlement with United Therapeutics resolved all six lawsuits, keeping Yutrepia available for PAH while giving up the PH-ILD indication and requiring substantial payments. Traders welcomed the reduced legal uncertainty and speculated about a short squeeze, while others focused on the lost market opportunity and financial burden.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is facing a sharp pullback as traders debate its high valuation and broader weakness in AI and semiconductor stocks, with upcoming earnings and guidance viewed as a test of demand for its data-center connectivity products. Some see the decline as a buying opportunity tied to continued AI infrastructure spending, while others expect further downside or a post-earnings selloff.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce Coronary Intravascular Lithotripsy System

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce Coronary Intravascular Lithotripsy System Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational...

Abbott initiates pivotal trial for Cephea device, an innovative treatment for mitral heart valve disease

Abbott initiates pivotal trial for Cephea device, an innovative treatment for mitral heart valve disease Abbott initiates pivotal trial for Cephea device, an innovative treatment for mitral heart valve diseasePR NewswireABBOTT PARK, Ill., Oct. 29, 2026 CROWN-MV trial will evaluate the safety and...

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Abbott launches whole-genome sequencing Oncodetect molecular residual disease (MRD) test to detect traces of cancer during and after treatment

Abbott launches whole-genome sequencing Oncodetect molecular residual disease (MRD) test to detect traces of cancer during and after treatment Abbott launches whole-genome sequencing Oncodetect molecular residual disease (MRD) test to detect traces of cancer during and after treatmentPR...

Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?

Key PointsAbbott Laboratories maintains a highly diversified healthcare business spanning medical technology, diagnostics, and nutrition...

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in...

Abbott's Q3 Earnings Call Focuses on Nutrition Spin-Off and Outlook

Abbott plans to spin off its $8.5B Nutrition business by 2027 while cutting its 2026 sales growth outlook amid diabetes pricing and electrophysiology challenges.

Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm

Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold FirmPR NewswireVANCOUVER, BC, Oct. 21, 2026 VANCOUVER, BC, Oct. 21, 2026 /PRNewswire/ -- Stock Preachers News Commentary - Three...

Abbott Laboratories Q3 2026 Earnings Call Transcript

Abbott Laboratories (NYSE:ABT) reported third-quarter financial results on Wednesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzingaread more...

• Reported GAAP EPS of $1.42 up 9.23% YoY
• Reported revenue of $13.01B up 14.46% YoY
• Abbott projects full-year 2026 comparable sales growth of approximately 6.0%, adjusted diluted EPS of $5.50 to $5.55, and fourth-quarter 2026 adjusted diluted EPS of $1.62 to $1.67; Abbott reaffirms the midpoint and tightens the range.

Abbott's operating and net earnings declined, Nutrition comparable sales fell during 9M26, and third-quarter specified items included approximately $670M for Gill and NEC claim resolutions.

Abbott's new product approvals expand offerings across diabetes, atrial fibrillation and cancer screening; Medical Devices growth was led by Electrophysiology and Rhythm Management, while Key Emerging Markets comparable sales increased 10.9%.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment focuses on branded generic pharmaceuticals that are manufactured worldwide and marketed and sold outside the United States, primarily in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternative care testing sites. The Nutritional Products segment oversees the worldwide sale of pediatric and adult nutritional products. The Medical Devices segment offers a broad range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as diabetes care and continuous glucose monitoring products. It also provides neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

ABT, FIG, IP Stocks Fell To 52-Week Lows Today: What's Happening?

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>ABT stock fell to a 52-week low of $90.29 in intraday trading as weak Covid-19 testing and U.S. pediatric nutrition, and other sectoral concerns weighed on its performance.&nbsp;</li><li>FIG stock fell to a 52-week low of $16.60 in Thursday’s intraday session as concerns over Anthropic’s AI design tool continued to linger.&nbsp;</li><li>IP stock fell to a 52-week low of $29.45 after its first-quarter results failed to meet Wall Street expectations.</li></ul><p>Abbott Laboratories (ABT), Figma Inc. (FIG), and International Paper Co. (IP) stocks were among those that hit fresh intraday lows on Thursday as investors grew skeptical over regulatory concerns, emerging competitive threats, and earnings results.</p><p>Shares of ABT fell about 0.6% at the close and IP stock closed down more than 9%. Meanwhile, FIG shares recovered from intraday lows, closing up about 5%.</p><h2 class="st-heading-2">Sectoral Concerns Weigh On Abbott</h2><p>The global healthcare company’s shares fell to a 52-week low of $90.29 in intraday trading, capping two consecutive months of declines.</p><p>Abbott has been facing pressure from declining demand for Covid-19 testing, market-share losses in pediatric nutrition, and other sectoral headwinds. Recent positive developments, including FDA clearance for its AI-powered coronary imaging platform Ultreon 3.0 Software, and positive data from four trials, have failed to meaningfully revive the stock’s performance.</p><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/abt">ABT stock</a> has remained in the ‘bearish’ territory over the past 24 hours amid ‘high’ message volumes. ABT shares have declined more than 26% this year.</p><h2 class="st-heading-2">Figma Swings On AI Concerns</h2><p><a href="https://stocktwits.com/symbol/FIG">FIG stock</a> fell to a 52-week low of $16.60 in Thursday’s intraday session before recovering to $17.70 at close. Although the design company has been under pressure over concerns around Anthropic’s artificial intelligence tool, retail investors in the company have largely dismissed concerns.</p><p>Meanwhile, according to Koyfin data, 12 analysts covering the stock have a 12-month average price target of $40.25, representing an upside potential of about 127% from the previous close.</p><p>FIG stock has declined nearly 53% this year, but retail traders on Stocktwits remain ‘bullish’ on the stock.</p><h2 class="st-heading-2">International Paper Declines On Weak Results</h2><p><a href="https://stocktwits.com/symbol/ip">IP stock</a> fell to a fresh 52-week low of $29.45 after it posted first-quarter (Q1) results that disappointed Wall Street and retail investors alike.</p><p>JPMorgan said in a note on Thursday that International Paper's Q1 EBITDA of $677 million was 3% below consensus and below its own guidance of $740 million, according to TheFly. The company’s guidance for the following quarter’s EBITDA was also 25% below consensus estimates at the mid-point. The firm said that the Q1 report was "worse than our negative catalyst watch envisioned."</p><p>JPMorgan has a Neutral rating and $46 price target on International Paper shares. Meanwhile, retail sentiment around the stock was ‘bullish’ at the time of writing. IP stock has lost more than 24% this year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The illustration shows the US flag, cash dollar banknotes and stock market indicators. Top US firms announced record buybacks this year. (Source: Getty Images)

Abbott Laboratories, Figma, and International Paper declined to yearly lows amid market pressures, AI threat, and weak earnings. 

Figma

International Paper Co.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$1.64	--	--	N/A
Q3 '26	$1.42	$1.42	0.03%	BEAT
Q2 '26	$1.31	$1.31	--	EXPECTED
Q1 '26	$1.14	$1.15	0.47%	BEAT
Q4 '25	$1.50	$1.50	0.29%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABT Earnings

Latest Earnings Results: Q3 '26

Historical Earnings